SCHEMBL6166256

SCHEMBL6166256

COc1ccc2nc(-c3ccccc3)cc(C(=O)N3CCC[C@H]3CO)c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.59
PLA2G2A P14555 2/20 0.57
POLB P06746 1/20 0.54
RAB9A P51151 1/20 0.54
TRPV1 Q8NER1 3/20 0.54
PREP P48147 1/20 0.49
SLC22A12 Q96S37 1/20 0.49
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
MEN1 O00255 1/20 0.49
TP53 P04637 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
KMT2A Q03164 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
BCHE P06276 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6163720 1.00 TDP1 (0.59) TDP1PLA2G2APOLBRAB9ATRPV1
SCHEMBL6162631 1.00 TDP1 (0.59) TDP1PLA2G2APOLBRAB9ATRPV1
SCHEMBL6163856 0.91 RAB9A (0.67) TDP1POLBRAB9ATRPV1PREP
SCHEMBL6163154 0.91 RAB9A (0.67) TDP1POLBRAB9ATRPV1PREP
SCHEMBL6165000 0.91 RAB9A (0.67) TDP1POLBRAB9ATRPV1PREP
SCHEMBL6166721 0.89 TRPV1 (0.61) TDP1POLBRAB9ATRPV1PREP
SCHEMBL6164640 0.89 TRPV1 (0.61) TDP1POLBRAB9ATRPV1PREP
SCHEMBL6164732 0.89 TRPV1 (0.61) TDP1POLBRAB9ATRPV1PREP
SCHEMBL6163110 0.86 DHODH (0.56) TRPV1SLC22A12KDM4EALDH1A1HPGD
SCHEMBL6163103 0.86 DHODH (0.56) TRPV1SLC22A12KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337523-B1 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORP (US) 2005-10-19 EP claimed
US-20040048867-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2004-03-11 US claimed
EP-1337523-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2003-08-27 EP claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US claimed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US claimed
WO-2002014269-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2002-02-21 WO claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161008-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 TDP1 745/4885PLA2G2A 1847/4885POLB 1324/4885
US-20040048867-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 TDP1 745/4885PLA2G2A 1847/4885POLB 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.